Loading...

Millendo Therapeutics, Inc.

MLND•NASDAQ
Healthcare
Biotechnology
$1.06
$-0.06(-5.36%)

Millendo Therapeutics, Inc. (MLND) Stock Overview

Explore Millendo Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.8/100

Key Financials

Market Cap11.1M
P/E Ratio-0.04
EPS (TTM)N/A
ROE-0.78%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$2.14

MLND Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Millendo Therapeutics, Inc. (MLND) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $2.14.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.04 and a market capitalization of 11.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for MLNDStats details for MLND are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for MLNDAnalyst Recommendations details for MLND are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

CEO

Dr. Julia Owens

Employees

12

Headquarters

110 Miller Ave Ste 100, Ann Arbor, MI

Founded

2012

Frequently Asked Questions

;